title: [The treatment of Parkinson's disease].
abstract: Parkinson's disease belongs to the most prevalent neurodegenerative disorders and manifests both with motor and non-motor symptoms. Symptomatic treatment of this disorder became more multifaceted over the past years: besides classical dopaminergic drugs and physiotherapy, novel invasive escalation treatment strategies became gold standard in many countries. On the other hand, non-motor symptoms significantly impacts quality of life in many patients which necessitates initiation of adequate therapy.
authors: Klinik für Neurologie, Universitätsspital Zürich.
authors: Christian R
authors: CR
authors: Baumann
authors: Daniel
authors: D
authors: Waldvogel
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D002230:Carbidopa / Q000009:adverse effects / Q000627:therapeutic use; D065098:Catechol O-Methyltransferase Inhibitors; D003131:Combined Modality Therapy; D046690:Deep Brain Stimulation; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000175:diagnosis / Q000628:therapy*; D026741:Physical Therapy Modalities
chemical_list: D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D018491:Dopamine Agonists; D004338:Drug Combinations; D008996:Monoamine Oxidase Inhibitors; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D002230:Carbidopa
keywords: Dopamin; Dopaminagonisten; Levodopa; Maladie de Parkinson; Parkinson's disease; Parkinson-Erkrankung; agonistes de la dopamine; dopamine; dopamine agonists; levodopa